Orexigen Therapeutics (OREX) : 4 analysts believe that the current prices are in a balance with the stocks fundamentals, hence they propose Hold on Orexigen Therapeutics (OREX). Zacks Investment Research suggests a Sell with a rank of 4. 1 analysts perceive the stock to be overvalued at the existing levels, hence their call is to Sell the stock.The median of all the 5 Wall Street Analysts endorse the stock as a Hold with a rating of 3.2.
Orexigen Therapeutics (OREX) : The highest level Orexigen Therapeutics (OREX) is projected to reach is $2 for the short term and the lowest estimate is at $1. The consolidated price target from 4 rating analysts who initiate coverage on the stock is $1.03 and the possibility the share price can swing is $0.69.
Orexigen Therapeutics (NASDAQ:OREX): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $0.43 and $0.43 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $0.44. The buying momentum continued till the end and the stock did not give up its gains. It closed at $0.43, notching a gain of 1.65% for the day. The total traded volume was 723,395 . The stock had closed at $0.43 on the previous day.
The company shares have dropped -90.61% from its 1 Year high price. On Jul 13, 2015, the shares registered one year high at $4.92 and the one year low was seen on May 19, 2016. The 50-Day Moving Average price is $0.44 and the 200 Day Moving Average price is recorded at $0.92.
Orexigen Therapeutics, Inc. (Orexigen) is a biopharmaceutical company. The Company is focused on the development of pharmaceutical product candidates for the treatment of obesity. The Companys product is Contrave, a fixed dose combination of bupropion hydrochloride (HCl) extended release (ER) and naltrexone HCl ER. The Companys product Contrave, is approved in the United States by the United States Food and Drug Administration (FDA) as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI), of around 30 kilograms per square meter (kg/m2) or greater (obese), or around 27 kilograms per square meter or greater (overweight) in the presence of at least one weight-related comorbid condition. The Company also submitted an application for marketing authorization with the European Medicines Agency (EMA) for Contrave under the name Mysimba.